Parkinson’s disease is the most common neurodegenerative disease after Alzheimer’s disease and belongs to the group of hypokinetic movement disorders. Atypical parkinsonian disorders represent a pathologically inhomogeneous group of rare neurodegenerative disorders which, compared to Parkinson’s disease, are characterized by a more malignant course and poorer therapeutic response. Neuroprotective or disease-modifying therapies are neither available for Parkinson’s disease nor for atypical parkinsonian disorders. The most effective substance for symptomatic therapy is still levodopa. Invasive therapy options available for Parkinson’s disease are not used in atypical parkinsonian disorders.